Literature DB >> 1701483

A synthetic peptide derived from the amino acid sequence of canine parvovirus structural proteins which defines a B cell epitope and elicits antiviral antibody in BALB c mice.

G F Rimmelzwaan1, J Carlson, F G UytdeHaag, A D Osterhaus.   

Abstract

Synthetic peptides, recombinant fusion proteins and mouse monoclonal antibodies were used to delineate a B cell epitope of the VP'2 structural protein of canine parvovirus (CPV). Although this epitope is not preferentially recognized in the normal antibody response to CPV, virus-specific antibodies could be induced in BALB/c mice with a synthetic peptide representing the epitope. The potential of this non-dominant B cell epitope to induce antiviral immunity in the presence of maternal CPV-specific antibodies, is discussed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701483     DOI: 10.1099/0022-1317-71-11-2741

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions.

Authors:  T Saikawa; S Anderson; M Momoeda; S Kajigaya; N S Young
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

2.  Different mechanisms of antibody-mediated neutralization of parvoviruses revealed using the Fab fragments of monoclonal antibodies.

Authors:  Christian D S Nelson; Laura M Palermo; Susan L Hafenstein; Colin R Parrish
Journal:  Virology       Date:  2007-01-09       Impact factor: 3.616

3.  Detection of canine parvovirus antigens with antibodies to synthetic peptides.

Authors:  M Vihinen-Ranta; E Lindfors; L Heiska; P Veijalainen; M Vuento
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

4.  Peptide vaccine against canine parvovirus: identification of two neutralization subsites in the N terminus of VP2 and optimization of the amino acid sequence.

Authors:  J I Casal; J P Langeveld; E Cortés; W W Schaaper; E van Dijk; C Vela; S Kamstrup; R H Meloen
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

5.  First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs.

Authors:  J P Langeveld; J I Casal; A D Osterhaus; E Cortés; R de Swart; C Vela; K Dalsgaard; W C Puijk; W M Schaaper; R H Meloen
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

6.  Expression of Aleutian mink disease parvovirus capsid proteins in defined segments: localization of immunoreactive sites and neutralizing epitopes to specific regions.

Authors:  M E Bloom; D A Martin; K L Oie; M E Huhtanen; F Costello; J B Wolfinbarger; S F Hayes; M Agbandje-McKenna
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

7.  Structural comparison of different antibodies interacting with parvovirus capsids.

Authors:  Susan Hafenstein; Valorie D Bowman; Tao Sun; Christian D S Nelson; Laura M Palermo; Paul R Chipman; Anthony J Battisti; Colin R Parrish; Michael G Rossmann
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

8.  B-cell epitopes of canine parvovirus: distribution on the primary structure and exposure on the viral surface.

Authors:  J P Langeveld; J I Casal; C Vela; K Dalsgaard; S H Smale; W C Puijk; R H Meloen
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

9.  The structure of a neutralized virus: canine parvovirus complexed with neutralizing antibody fragment.

Authors:  W R Wikoff; G Wang; C R Parrish; R H Cheng; M L Strassheim; T S Baker; M G Rossmann
Journal:  Structure       Date:  1994-07-15       Impact factor: 5.006

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.